Objectives: The etiology of myocardial ischemia/reperfusion (I/R) injury is multifactorial, but activation of the innate immune system and the resulting inflammatory response are important components of I/R injury. The aim of this study was to investigate the protective effect of a hemoglobin-based oxygen carrier (HBOC) on cold I/R heart and to explore the underlying mechanisms. Methods: Isolated Sprague-Dawley rat hearts were perfused in the Langendorff mode. After 30 min of basal perfusion, rat hearts were arrested with histidine-tryptophan-ketoglutarate solution (HTKs) with or without an HBOC and hypothermically stored (4°C) for 9 or 14 h, followed by 2 h of reperfusion. Results: Compared with HTKs alone, the HBOC in HTKs greatly improved heart contraction and decreased infarct size, necrosis and apoptosis, which was related to the reduced expression of Toll-like receptor 2 (TLR 2), TLR 4, TNF-α, IL-1β and nuclear factor-ĸB (NF-ĸB) activation. Conclusions: Our results demonstrated that the HBOC protected isolated rat heart from cold I/R injury and this protection was associated with attenuation of the expression of the TLR 2 and TLR 4/NF-ĸB signaling pathway, which may down-regulate the inflammatory response.

Keywords:
Hemoglobin-based oxygen carrier, Ischemia/reperfusion injury, Inflammation, Toll-like receptors
1.
Yellon DM, Hausenloy DJ: Myocardial reperfusion injury. N Engl J Med 2007;357:1121–1135.
2.
Inserte J, Barrabes JA, Hernando V, Garcia Dorado D: Orphan targets for reperfusion injury. Cardiovasc Res 2009;83:169–178.
3.
Murphy E, Steenbergen C: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev 2008;88:581–609.
4.
Gustafsson AB, Gottlieb RA: Heart mitochondria: gates of life and death. Cardiovasc Res 2008;77:334–343.
5.
Saeed SA, Waqar MA, Zubairi AJ, et al: Myocardial ischaemia and reperfusion injury: reactive oxygen species and the role of neutrophil. J Coll Physicians Surg Pak 2005;15:507–514.
6.
Parish RC, Evans JD: Inflammation in chronic heart failure. Ann Pharmacother 2008;42:1002–1016.
7.
Miyake K: Innate immune sensing of pathogens and danger signals by cell surface Toll-like receptors. Semin Immunol 2007;19:3.
8.
Kaczorowski DJ, Mollen KP, Edmonds R, et al: Early events in the recognition of danger signals after tissue injury. J Leukoc Biol 2008;83:546.
9.
Mollen KP, Anand RJ, Tsung A, et al: Emerging paradigm: Toll-like receptor 4-sentinel for the detection of tissue damage. Shock 2006;26:430.
10.
Standl T, Freitag M, Burmeister MA, Horn EP, Wilhelm S, Am Esch JS: Hemoglobin-based oxygen carrier HBOC-201 provides higher and faster increase in oxygen tension in skeletal muscle of anemic dogs than do stored red blood cells. J Vasc Surg 2006;37:859–865.
11.
George I, Yi GH, Schulman, AR, Morrow BT, Cheng Y, Gu A, Zhang G, Oz MC, Burkhoff D, Wang JA: Polymerized bovine hemoglobin oxygen carrier preserves regional myocardial function and reduces infarct size after acute myocardial ischemia. Am J Physiol Heart Circ Physiol 2006;291:H1126–H1137.
12.
Li T, Li J, Liu J, Zhang P, Wu W, Zhou R, Li G, Zhang W, Yi M, Huang H: Polymerized placenta hemoglobin attenuates ischemia/reperfusion injury and restores the nitroso-redox balance in isolated rat heart. Free Radic Biol Med 2009;46:397–405.
13.
Li T, Liu J, Yang Q, Wu W, Zhang P, Yang J, Li J, Zhang W, Yang C: Polymerized placenta hemoglobin improves cardiac functional recovery and reduces infarction size of isolated rat heart. Artif Cells Blood Substit Immobil Biotechnol 2009;37:48–52.
14.
Yang J, Yang J, Ding JW, Chen LH, et al: Sequential expression of TLR4 and its effects on the myocardium of rats with myocardial ischemia-reperfusion injury. Inflammation 2008;31:304–312.
15.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2006;3:RESEARCH0034.
16.
Caswell JE, Strange MB, Rimmer DM 3rd, Gibson MF, Cole P, Lefer DJA: Novel hemoglobin-based blood substitute protects against myocardial reperfusion injury. Am J Physiol Heart Circ Physiol 2005;288:H1796–H1801.
17.
Serruys P, Vranckx P, Slagboom T, Regar E, Meliga E, de Winter R, Heyndrickx G, Schuler G, van Remortel E, Dubé GP, Symons J: Haemodynamic effects, safety, and tolerability of haemoglobin-based oxygen carrier-201 in patients undergoing PCI for CAD. EuroIntervention 2008;3:600–609.
18.
Olofsson C, Nygards EB, Ponzer S, Fagrell B, Przybelski R, Keipert PE, Winslow N, Winslow RM: A randomized, single-blind, increasing dose safety trial of an oxygen-carrying plasma expander (Hemospan) administered to orthopaedic surgery patients with spinal anaesthesia. Transfus Med 2008;18:28–39.
19.
Yu B, Shahid M, Egorina EM, Sovershaev MA, et al: Endothelial dysfunction enhances vasoconstriction due to scavenging of nitric oxide by a hemoglobin-based oxygen carrier. Anesthesiology 2010;112:586–594.
20.
Li T, Yu R, Zhang HH, Wang H, Liang WG, Yang XM, Yang CM: A method for purification and viral inactivation of human placenta hemoglobin. Artif Cells Blood Substit Immobil Biotechnol 2006;34:175–188.
21.
Wu W, Yang Q, Li T, Zhang P, Zhou R, Yang C: Hemoglobin-based oxygen carriers combined with anticancer drugs may enhance sensitivity of radiotherapy and chemotherapy to solid tumors. Artif Cells Blood Substit Immobil Biotechnol 2009;37:163–165.
22.
You Z, Li T, Yang C, Wu H, Zeng Y: Comparison of the cardioprotective effect of deoxygenated hemoglobin-based oxygen carrier (HBOC) pretreatment and ischemia preconditioning. Artif Cells Blood Substit Immobil Biotechnol 2011;39:7–11.
23.
Asanuma H, Nakai K, Sanada S, Minamino T, Takashima S, et al: S-nitrosylated and pegylated hemoglobin, a newly developed artificial oxygen carrier, exerts cardioprotection against ischemic hearts. J Mol Cell Cardiol 2007;42:924–930.
24.
Burmeister MA, Rempf C, Standl TG, Rehberg S, Bartsch-Zwemke S, Krause T, Tuszynski S, Gottschalk A, Schulte am Esch J: Effects of prophylactic or therapeutic application of bovine haemoglobin HBOC-200 on ischaemia-reperfusion injury following acute coronary ligature in rats. Br J Anaesth 2005;95:737–745.
25.
O’Neill LAJ: How Toll-like receptors signal: what we know and what we don’t know. Curr Opin Immunol 2006;18:3–9.
26.
Oyama J, Blais C Jr, Liu X, et al: Reduced myocardial ischemia-reperfusion injury in Toll-like receptor 4-deficient mice. Circulation 2004;109:784.
27.
Sha Y, Zmijewski J, Xu Z, et al: HMGB1 develops enhanced proinflammatory activity by binding to cytokines. J Immunol 2008;180:2531.
28.
Liew FY, Xu D, Brint EK, O’Neill LAJ: Negative regulation of Toll-like receptor-mediated immune responses. Nat Rev Immunol 2005;5:446–458.
29.
Fialkow L, Wang Y, Downey GP: Reactive oxygen and nitrogen species as signaling molecules regulating neutrophil function. Free Radic Biol Med 2007;42:153–164.
30.
Kim JH, Na HJ, Kim CK, Kim JY, Ha KS, Lee H, et al: The nonprovitamin A carotenoid, lutein, inhibits NF-ĸB-dependent gene expression through redox-based regulation of the phosphatidylinositol 3-kinase/PTEN/Akt and NF-ĸB-inducing kinase pathways: role of H2O2 in NF-ĸB activation. Free Radic Biol Med 2008;45:885–896.
31.
Arslan F, De Kleijn DPV, Timmers L, Doevendans PA, Pasterkamp G: Bridging innate immunity and myocardial ischemia/reperfusion injury: the search for therapeutic targets. Curr Pharm Des 2008;14:1205–1216.
32.
Palm NW, Medzhitov R: Pattern recognition receptors and control of adaptive immunity. Immunol Rev 2009;227:221–233.
33.
Zahringer U, Lindner B, Inamura S, Heine H, Alexander C: TLR2 – promiscuous or specific? A critical re-evaluation of a receptor expressing apparent broad specificity. Immunobiology 2008;213:205–224.
34.
Aprahamian CJ, Lorenz RG, Harmon CM, Dimmit RA: Toll-like receptor 2 is protective of ischemia-reperfusion-mediated small-bowel injury in a murine model. Pediatr Crit Care Med 2008;9:105–109.
35.
Cavassani KA, Ishii M, Wen H, Schaller MA, Lincoln PM, Lukacs NW, et al: TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events. J Exp Med 2008;205:2609–2621.
36.
Khandoga AG, Khandoga A, Anders HJ, Krombach F: Postischemic vascular permeability requires both TLR-2 and TLR-4, but only TLR-2 mediates the transendothelial migration of leukocytes. Shock 2009;31:592–598.
37.
Ito I, Fukazawa J, Yoshida M: Post-translational methylation of high mobility group box 1 (HMGB1) causes its cytoplasmic localization in neutrophils. J Biol Chem 2007;282:16336–16344.
38.
Lambeth JD: NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 2004;4:181–189.
39.
Kazama H, Ricci JE, Herndon JM, Hoppe G, Green DR, Ferguson TA: Induction of immunological tolerance by apoptotic cells requires caspase-dependent oxidation of high-mobility group box-1 protein. Immunity 2008;29:21–32.
40.
Park HS, Jung HY, Park EY, Kim J, Lee WJ, Bae YS: Cutting edge: direct interaction of TLR4 with NAD(P)H oxidase 4 isozyme is essential for lipopolysaccharide-induced production of reactive oxygen species and activation of NF-kappa B. J Immunol 2004;173:3589–3593.
41.
Clarke SJ, Khaliulin I, Das M, Parker JE, Heesom KJ, Halestrap AP: Inhibition of mitochondrial permeability transition pore opening by ischemic preconditioning is probably mediated by reduction of oxidative stress rather than mitochondrial protein phosphorylation. Circ Res 2008;102:1082–1090.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.